Table 3.

Patient Baseline Characteristics for Comparison between Vonoprazan and PPI, and Rates of Eradication.

	First-line therapy										Second-line therapy
	Baseline characteristics					Eradication rate					Baseline characteristics					Eradication rate
	VAC		PAC		p values	VAC	PAC		p values		VAM		PAM		p values	VAM	PAM	p values
All	415		757			92.5	83.9		<0.001		48		108			93.8	90.7	0.390
Age	61.0	[50.0-68.0]	61.0	[52.0-69.0]	0.631						67.0	[57.3-73.0]	59.5	[45.5-68.0]	0.003
≤39	39	(9.40)	74	(9.80)		94.9	66.2		0.001		4	(8.3)	21	(19.4)		100.0	95.2	0.840
40-49	60	(14.5)	81	(10.7)		96.7	86.4	*	0.038		2	(4.2)	12	(11.1)		100.0	83.3	0.725
50-59	93	(22.4)	194	(25.6)		95.7	87.1	**	0.024		9	(18.8)	21	(19.4)		100.0	90.5	0.483
60-69	136	(32.8)	227	(30.0)		91.9	86.3	**	0.108		16	(33.3)	30	(27.8)		93.8	100.0	0.348
≥70	87	(21.0)	181	(23.9)		86.2	83.4	*	0.558		17	(35.4)	24	(22.2)		88.2	79.2	0.374
Gender					0.316										0.020
male	196	(47.2)	370	(48.9)		93.4	85.1		0.004		14	(29.2)	52	(48.1)		100.0	92.3	0.376
female	219	(52.8)	387	(51.1)		91.8	82.7		0.002		34	(70.8)	56	(51.9)		91.2	89.3	0.538
Atrophy					0.202										0.185
mild	202	(48.7)	351	(34.6)		94.1	83.5		<0.001		18	(37.5)	53	(49.1)		100.0	92.5	0.301
severe	204	(49.2)	396	(52.3)		90.7	83.8		0.021		27	(56.3)	54	(50.0)		88.9	88.9	0.634

Values are shown as n (%) or median [IQR]. P values were calculated using a chi-square test and Mann-Whitney’s test.

Values for success of eradication therapy are shown as a percentage. P values for first- and second-line therapy were calculated using a chi-square test and Fisher’s exact test, respectively.

*p<0.05, vs. ≤39 years; **p<0.01, vs. ≤39 years (Steel-Dwass test).

VAC: vonoprazan, amoxicillin, and clarithromycin, PAC: proton-pump inhibitor, amoxicillin, and clarithromycin, VAM: vonoprazan, amoxicillin, and metronidazole, PAM: proton-pump inhibitor, amoxicillin, and metronidazole